Biosion Secures Licensing Deal with Aclaris Therapeutics for Global Rights to BSI-045B and BSI-502
Biosion, a clinical stage biotech company with operations in Delaware, US, and China, has entered...
Biosion
Biosion’s Bosakitug Shows Positive Results in Atopic Dermatitis Phase II POC Study
Biosion, a clinical-stage biotechnology company with operations in Delaware, U.S., and China, has announced key...
Biosion’s SIRPα-Targeting Monoclonal Antibody BSI-082 Clears US FDA Clinical Trial Hurdle
Biosion, a global clinical-stage biotechnology company dedicated to developing antibody-based therapies for immune and oncologic...
OBI Pharma Gets US FDA Green Light for TROP2 Targeting ADC Cancer Therapy Clinical Study
OBI Pharma (4174.TWO), partner to Biosion Inc., has announced that it has received approval from...
Biosion Secures Series B+ Financing to Advance Antibody-Based Therapies Pipeline
Biosion, a global, clinical-stage biotech company dedicated to developing antibody-based therapies for immune and oncologic...
Biosion Receives FDA Approval for Phase II Study of TSLP mAb BSI-045B
Global, clinical-stage biotech company Biosion, dedicated to developing antibody-based therapies for immune and oncologic diseases,...
Biosion Completes Series B Financing Round Led by Guangfa Xinde Investment
Biosion, a global, clinical-stage biotech committed to developing antibody-based therapies targeting immune and oncologic diseases,...
Biosion and ImmunoGen Collaborate on Cancer ADCs
China-based Biosion Inc. announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the...
Pyxis Oncology Receives FDA Approval for Biosion’s PYX-106 Clinical Trials
China-based Biosion, Inc’s US partner Pyxis Oncology, Inc. (NASDAQ: PYXS) announced receiving clinical trial approval...